Published in Immunology on May 01, 2002
Induction of emetic response to staphylococcal enterotoxins in the house musk shrew (Suncus murinus). Infect Immun (2003) 1.03
Two common structural motifs for TCR recognition by staphylococcal enterotoxins. Sci Rep (2016) 0.75
Exotoxins of Staphylococcus aureus. Clin Microbiol Rev (2000) 7.35
Crystal structure of a T-cell receptor beta-chain complexed with a superantigen. Nature (1996) 7.11
The outline structure of the T-cell alpha beta receptor. EMBO J (1988) 4.37
egc, a highly prevalent operon of enterotoxin gene, forms a putative nursery of superantigens in Staphylococcus aureus. J Immunol (2001) 4.36
Three-dimensional structure of a human class II histocompatibility molecule complexed with superantigen. Nature (1994) 3.60
Antigen/MHC-specific T cells are preferentially exported from the thymus in the presence of their MHC ligand. Cell (1989) 3.29
Identification and purification of a new staphylococcal enterotoxin, H. Appl Environ Microbiol (1995) 2.02
Crystal structure of the superantigen staphylococcal enterotoxin type A. EMBO J (1995) 1.99
Identification and characterization of novel superantigens from Streptococcus pyogenes. J Exp Med (1999) 1.98
Characterization and biological properties of a new staphylococcal exotoxin. J Exp Med (1994) 1.91
Biochemical and biological properties of Staphylococcal enterotoxin K. Infect Immun (2001) 1.80
Three-dimensional structure of the complex between a T cell receptor beta chain and the superantigen staphylococcal enterotoxin B. Immunity (1998) 1.68
Staphylococcal enterotoxin A has two cooperative binding sites on major histocompatibility complex class II. J Exp Med (1995) 1.58
Characterization of two distinct MHC class II binding sites in the superantigen staphylococcal enterotoxin A. EMBO J (1995) 1.54
Identification of HLA-DR1 beta chain residues critical for binding staphylococcal enterotoxins A and E. J Exp Med (1992) 1.52
Superantigens - powerful modifiers of the immune system. Mol Med Today (2000) 1.43
Structure of toxic shock syndrome toxin 1. Biochemistry (1993) 1.43
Crystal structure of the superantigen enterotoxin C2 from Staphylococcus aureus reveals a zinc-binding site. Structure (1995) 1.42
A mutational analysis of the binding of staphylococcal enterotoxins B and C3 to the T cell receptor beta chain and major histocompatibility complex class II. J Exp Med (1998) 1.39
STAT5 interaction with the T cell receptor complex and stimulation of T cell proliferation. Science (1999) 1.38
Crystal structure of microbial superantigen staphylococcal enterotoxin B at 1.5 A resolution: implications for superantigen recognition by MHC class II molecules and T-cell receptors. J Mol Biol (1998) 1.38
Cross-linking of major histocompatibility complex class II molecules by staphylococcal enterotoxin A superantigen is a requirement for inflammatory cytokine gene expression. J Exp Med (1995) 1.30
The crystal structure of staphylococcal enterotoxin type D reveals Zn2+-mediated homodimerization. EMBO J (1996) 1.23
Crystal structure of a superantigen bound to MHC class II displays zinc and peptide dependence. EMBO J (2001) 1.21
In vivo anergized CD4+ T cells express perturbed AP-1 and NF-kappa B transcription factors. Proc Natl Acad Sci U S A (1996) 1.21
Immunopharmacology of the superantigen staphylococcal enterotoxin A in T-cell receptor V beta 3 transgenic mice. Immunology (1993) 1.13
Vbeta-dependent stimulation of bovine and human T cells by host-specific staphylococcal enterotoxins. Infect Immun (1997) 1.09
Role of the T cell receptor ligand affinity in T cell activation by bacterial superantigens. J Biol Chem (2001) 1.05
Role of the T cell receptor alpha chain in stabilizing TCR-superantigen-MHC class II complexes. Immunity (1999) 1.04
Understanding the mechanism of action of bacterial superantigens from a decade of research. Immunol Rev (1999) 1.02
Human T cell clones exerting multiple cytolytic activities show heterogeneity in susceptibility to inhibition by monoclonal antibodies. J Immunol (1984) 1.01
Cutting edge: TCR stimulation by antibody and bacterial superantigen induces Stat3 activation in human T cells. J Immunol (1999) 1.01
The crystal structure of staphylococcal enterotoxin H: implications for binding properties to MHC class II and TcR molecules. J Mol Biol (2000) 1.00
Production of a toxic shock syndrome toxin variant by Staphylococcus aureus strains associated with sheep, goats, and cows. J Clin Microbiol (1989) 0.97
Staphylococcal enterotoxin H displays unique MHC class II-binding properties. J Immunol (1999) 0.94
Staphylococcal enterotoxin D is a promiscuous superantigen offering multiple modes of interactions with the MHC class II receptors. J Immunol (1998) 0.93
Quantitative fluorometric assay for detection and characterization of Fc receptors. Methods Enzymol (1983) 0.90
Mutations in the MHC class II binding domains of staphylococcal enterotoxin A differentially affect T cell receptor Vbeta specificity. J Immunol (1996) 0.86
Molecular characterization and role in T cell activation of staphylococcal enterotoxin A binding to the HLA-DR alpha-chain. J Immunol (1997) 0.82
A mutation of F47 to A in staphylococcus enterotoxin A activates the T-cell receptor Vbeta repertoire in vivo. Infect Immun (1997) 0.79
T-cell cytotoxicity assays for studying the functional interaction between the superantigen staphylococcal enterotoxin A and T-cell receptors. Methods Mol Biol (2000) 0.78
Phase I dose escalation, pharmacokinetic and pharmacodynamic study of naptumomab estafenatox alone in patients with advanced cancer and with docetaxel in patients with advanced non-small-cell lung cancer. J Clin Oncol (2009) 1.06
Staphylococcal enterotoxin H induces V alpha-specific expansion of T cells. J Immunol (2003) 1.05
Crystal structure of a SEA variant in complex with MHC class II reveals the ability of SEA to crosslink MHC molecules. Structure (2002) 0.98
Cutting edge: Evidence of direct TCR alpha-chain interaction with superantigen. J Immunol (2007) 0.88
Immunotherapy with tumor-targeted superantigens (TTS) in combination with docetaxel results in synergistic anti-tumor effects. Int Immunopharmacol (2009) 0.87
Identification of the antigenic epitopes in staphylococcal enterotoxins A and E and design of a superantigen for human cancer therapy. J Mol Biol (2003) 0.86
Systemic IGF-I administration stimulates the in vivo growth of early, but not advanced, renal cell carcinoma. Int J Cancer (2008) 0.82
The tumor targeted superantigen ABR-217620 selectively engages TRBV7-9 and exploits TCR-pMHC affinity mimicry in mediating T cell cytotoxicity. PLoS One (2013) 0.81
Naptumomab estafenatox: targeted immunotherapy with a novel immunotoxin. Curr Oncol Rep (2014) 0.79
Influence of IGF-IR stimulation or blockade on proliferation of human renal cell carcinoma cell lines. Int J Oncol (2004) 0.78
Spectrophotometric methods for the determination of superantigen structure and stability. Methods Mol Biol (2003) 0.76